Novel c‐Abl inhibitors have been developed that may not bind to efflux transporters and, therefore, have the potential to provide greater brain concentrations and saturating levels of c‐Abl inhibition, show promising benefits in preclinical models of PD, and have demonstrated good safety profiles in early clinical studies albeit in a limited number of PD patients. Here, ABL1 is linked to Parkinson disease.